The cardiovascular risk of febuxostat among patients with hyperuricemia or gout compared with allopurinol: A population-based study in Taiwan

被引：0
|
作者：
Huang, Chien-Huei [1 ]
Su, Chien-Chou [2 ,3 ]
Liu, Pheng-Ying Yeh [1 ]
Yang, Yea-Huei Kao [2 ,3 ]
Cheng, Ching-Lan [2 ,3 ]
机构：
[1] Natl Cheng Kung Univ Hosp, Dept Pharm, Tainan, Taiwan
[2] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Hlth Outcome Res Ctr, Tainan, Taiwan
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2018年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
85
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [41] Risk of myocardial infarction among patients with gout: a nationwide population-based study
    Kuo, Chang-Fu
    Yu, Kuang-Hui
    See, Lai-Chu
    Chou, I-Jun
    Ko, Yu-Shien
    Chang, Hsiao-Chun
    Chiou, Meng-Jiun
    Luo, Shue-Fen
    RHEUMATOLOGY, 2013, 52 (01) : 111 - 117
  • [42] Risk of Stroke Among Patients with Gout in Taiwan: A Nationwide Population Study
    Tsai, Ping-Han
    Kuo, Chang-Fu
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [43] Gout Augments the Risk of Cardiovascular Disease in Patients With Psoriasis: A Population-Based Cohort Study
    Chen, Zhiyong
    Xu, Yiwen
    Chen, Miao
    Cui, Ran
    Wang, Yu-Hsun
    Dai, Sheng-Ming
    Wei, James Cheng-Chung
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [44] Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis
    Deng, Jian-Hao
    Zhang, Jia-Xing
    CLINICAL CARDIOLOGY, 2022, 45 (07) : 685 - 686
  • [45] The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES?
    Katsiki, Niki
    Borghi, Claudio
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (17) : 1853 - 1856
  • [46] Allopurinol Therapy in Gout Patients Does Not Associate with Beneficial Cardiovascular Outcomes: A Population-Based Matched-Cohort Study
    Kok, Victor C.
    Horng, Jorng-Tzong
    Chang, Wan-Shan
    Hong, Ya-Fang
    Chang, Tzu-Hao
    PLOS ONE, 2014, 9 (06):
  • [47] Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study
    H-J Shih
    M-C Kao
    P-S Tsai
    Y-C Fan
    C-J Huang
    Prostate Cancer and Prostatic Diseases, 2017, 20 : 328 - 333
  • [48] Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol
    Zembrzuska, Hanna
    Gao, Yubo
    Girotra, Saket
    Lund, Brian
    Saag, Kenneth
    Curtis, Jeff Rey
    Vaughan-Sarrazin, Mary
    Singh, Namrata
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [49] Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study
    Shih, H-J
    Kao, M-C
    Tsai, P-S
    Fan, Y-C
    Huang, C-J
    PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (03) : 328 - 333
  • [50] AS COMPARED WITH ALLOPURINOL ONLY FEBUXOSTAT PRESERVES VASCULAR FUNCTION IN PATIENTS WITH CHRONIC TOPHACEOUS GOUT
    Tausche, A-K.
    Christoph, M.
    Forkmann, M.
    Richter, U.
    Aringer, M.
    Wunderlich, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 704 - 704
12345